A new Indian patent granted to the University of Hyderabad marks an important step toward developing a multipurpose approach for preventing sexually transmitted infections (STIs) while addressing inflammation and contraception through a single topical platform. Indian Patent No. 602689, granted on September 16, 2026, covers methods and compositions based on lactoferrin nanoparticles loaded with curcumin in combination with antiretroviral drugs such as efavirenz, tenofovir or dapivirine.
The innovation lies not simply in combining existing compounds, but in using lactoferrin—a naturally occurring protein—as a nanoparticle delivery vehicle for local vaginal administration. The patented formulations are designed to bring antiviral and anti-inflammatory components together while incorporating the contraceptive potential of curcumin. The patent specifically claims these combinations.
Laboratory and animal studies described in the patent provide encouraging evidence for practical applicability. The nanoparticles demonstrated controlled, pH-dependent drug release, sustained antiviral activity, compatibility with Lactobacillus, and increased local drug availability following vaginal administration. The nanoformulations also showed lower systemic drug absorption than corresponding soluble formulations and reduced tissue damage in the reported animal studies.
The significance of the technology is its multipurpose prevention strategy, rather than requiring separate strategies for infection prevention, inflammation and contraception, one locally administered platform could potentially address several needs simultaneously.